{"nctId":"NCT04090580","briefTitle":"Impact on Glycemic Variability in Newly Onset T2DM Patients Initiating Dapagliflozin Plus Metformin Versus Metformin Alone","startDateStruct":{"date":"2019-10-27","type":"ACTUAL"},"conditions":["Type 2 Diabetes"],"count":88,"armGroups":[{"label":"DAPAGLIFLOZIN 10 mg/day + METFORMIN 2000 mg/day for 12 weeks","type":"EXPERIMENTAL","interventionNames":["Diagnostic Test: Continuous glucose monitoring"]},{"label":"METFORMIN 2000 mg/day for 12 weeks","type":"ACTIVE_COMPARATOR","interventionNames":["Diagnostic Test: Continuous glucose monitoring"]}],"interventions":[{"name":"Continuous glucose monitoring","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects \\> 18-77 years-old\n* Both Male and female\n* Hba1c ≥ 7.5 % and ≤12%\n* BMI \\> 25 and \\<45 kg/m2\n* Type 2 diabetes diagnosis, drug-naive\n\nExclusion Criteria:\n\n* Hba1c \\> 12%\n* Creatinine clearance CKD-EPI: \\< 60 mL/min\n* LADA or Type 1 diabetes\n* Gestational diabetes\n* Clinically significant disease like: hepatic, hematological, oncological, psychiatric or rheumatic disease.\n* Symptoms of marked uncontrolled diabetes: (marked poliuria or polidipsia + 10% weight loss prior the last 3 months enrollement)\n* Known hypersensitivity to dapagliflozin or any of the excipients of the product\n* eGFR persistently \\<45 mL/min/1.73 m2\n* Unstable or rapidly progressing renal disease\n* Patients with severe hepatic impairment (Child-Pugh class C)\n* Any major CV event/Vascular Disease within 3 months prior to signing the consent at enrollment, as assessed by the investigator\n* For women only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"77 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"ΔHbA1c","description":"Difference between serum HbA1c before treatment (W0) and at the end of intervention (W12) expressed in percentage.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":null},{"groupId":"OG001","value":"-1.6","spread":null}]}]}]},{"type":"PRIMARY","title":"ΔMAGE","description":"● Calculation of Mean Amplitude of Glucose Excursion (MAGE):\n\n* In the first step, all local maximum/minimum values are determined.\n* The next step is an evaluation of maximum/minimum pairs against the standard deviation (SD).\n* If the difference from minimum to maximum is greater than the SD, this variation from the mean measurement is retained.\n* If the local maximum/minimum is less than 1 SD, it is excluded from further calculations.\n* These channels are retained and summed to achieve the MAGE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Δweight","description":"The difference between weight before the treatment period (W0) and the end of the intervention is calculated and expressed as delta for results interpretation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":null},{"groupId":"OG001","value":"-0.7","spread":null}]}]}]},{"type":"PRIMARY","title":"ΔTIR %Target 70-180 mg/dL","description":"Time in range is defined as the percentage of time that the patient's blood glucose is between 70-180 mg/dL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.5","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Δinsulin","description":"Delta insulin is defined as the difference in insulin plasma concentration before treatment (W0) and at the end of the intervention (W12).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Δsystolic Blood Pressure","description":"It is defined as the difference in systolic blood pressure before treatment (W0) and after the end of intervention (W12)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"ΔTriglycerides mg/dL","description":"It is defined as the difference in triglycerides plasma concentration before and at the end of intervention (W12-W0)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.5","spread":null},{"groupId":"OG001","value":"-21.5","spread":null}]}]}]},{"type":"SECONDARY","title":"ΔUric Acid","description":"It is defined as the difference in plasma uric acid concentration before and at the end of intervention (W12-W0)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":42},"commonTop":[]}}}